FMC - Florissant is a medicare approved dialysis facility center in Florissant, Missouri and it has 13 dialysis stations. It is located in Saint Louis county at 577 Hodershell Road, Florissant, MO, 63031. You can reach out to the office of FMC - Florissant at (314) 831-2178. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - Florissant has the following ownership type - Profit. It was first certified by medicare in June, 2009. The medicare id for this facility is 262633 and it accepts patients under medicare ESRD program.
| Name | FMC - Florissant |
|---|---|
| Location | 577 Hodershell Road, Florissant, Missouri |
| No. of Dialysis Stations | 13 |
| Medicare ID | 262633 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 577 Hodershell Road, Florissant, Missouri, 63031 | |
| (314) 831-2178 | |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
| NPI Number | 1184860371 |
| Organization Name | Fresenius Medical Care Florissant |
| Doing Business As | Bio-medical Applications Of Missouri Inc |
| Address | 577 Howdershell Rd Florissant, Missouri, 63031 |
| Phone Number | (314) 831-2178 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 33 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 21 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 60 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 527 |
| Percentage of adult patients getting regular hemodialysis at the center | 91 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 25 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 208 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 87 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - Florissant with elevated calcium levels.
| Patients with hypercalcemia | 86 |
| Hypercalcemia patient months | 805 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 86 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 51 |
| Patient months included in arterial venous fistula and catheter summaries | 370 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 68 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 21 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 79 |
| Hospitalization Rate in facility | 175.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 300.4 |
| Hospitalization Rate: Lower Confidence Limit | 105.4 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - Florissant were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.6 |
| Readmission Rate: Lower Confidence Limit | 12.9 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - Florissant get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .38 (As Expected) |
| SIR: Upper Confidence Limit | 1.26 |
| SIR: Lower Confidence Limit | .06 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - Florissant's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 71 |
| Transfusion Rate in facility | 18.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 66 |
| Transfusion Rate: Lower Confidence Limit | 6.3 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC - Florissant lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 380 |
| Mortality Rate in facility | 13.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 18.4 |
| Mortality Rate: Lower Confidence Limit | 9.6 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago
Metro Dialysis Center - North Location: 2 Grandview Plaza, Florissant, Missouri, 63033 Phone: (314) 831-7990 |
Quality Care Dialysis Centers - North County Location: 6865 Parker Rd., Florissant, Missouri, 63033 Phone: (314) 653-6100 |
North Saint Louis County Dialysis Location: 13119 New Halls Ferry Road, Florissant, Missouri, 63033 Phone: (314) 838-3252 |
Cross Keys Dialysis Location: 14001 New Halls Ferry Rd #133, Florissant, Missouri, 63033 Phone: (314) 839-7416 |
News Archive
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.
Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.
Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win® channel partner program, bringing the program's partner count to 30 organizations.
People will be able to get a drug that can reduce the risk of heart attacks without a prescription from this summer, the government announced today.
› Verified 5 days ago